Australia North America South America Eastern Europe Western Europe Middle East Central America Asia Africa
Dadra and Nagar Haveli Himachal Pradesh Andaman and Nicobar Islands Nagaland Pondicherry Uttarakhand Daman and Diu Lakshadweep South India North India East India Assam Arunachal Pradesh Bihar Chandigarh Goa Haryana Jammu and Kashmir Jharkhand Karnataka Madhya Pradesh Maharashtra Mizoram Meghalaya Manipur Rajasthan Sikkim Tamil Nadu Telangana Tripura West Bengal Kerala Delhi Gujarat Punjab Andhra Pradesh Central India Odisha West India Chhattisgarh Uttar Pradesh All India
GMP/WHOGMP/NAFDAC/COA/COPP/Manufacturing License/Free sale certificate/Dossier.
Product Description
The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by people 12 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized.